Cephalon, Mylan Drop Patents From Nuvigil Dispute

Law360, New York (July 29, 2010, 2:41 PM EDT) -- Cephalon Inc. and generic-drug company Mylan Pharmaceuticals Inc. have agreed to drop claims related to two of three patents involved an infringement suit over narcolepsy drug Nuvigil.

The companies dropped claims and counterclaims over Cephalon-held U.S. Patent Number RE37,516 E, according to an order Wednesday from Judge Gregory M. Sleet of the U.S. District Court for the District of Delaware.

Cephalon accused Mylan of infringing that patent, as well as U.S. Patent Number 7,132,570, through an abbreviated new drug application for generic armodafinil, which is marketed...
To view the full article, register now.